AstraZeneca Completes Amolyt Pharma Acquisition

Amolyt Pharma, a clinical-stage biopharmaceutical company focusing on therapeutic peptides for rare endocrine and related diseases, announced the completion of its acquisition by AstraZeneca. This acquisition enhances AstraZeneca's Alexion division, specifically its late-stage pipeline for rare diseases, and strengthens its bone metabolism franchise with the addition of eneboparatide (AZP-3601). Eneboparatide is an investigational therapeutic peptide in Phase III, designed to address key therapeutic objectives for hypoparathyroidism.

Hypoparathyroidism is a condition characterized by a deficiency in parathyroid hormone (PTH) production, leading to significant disruptions in calcium and phosphate balance. This imbalance can result in severe symptoms and complications, including chronic kidney disease. The addition of eneboparatide to Alexion's portfolio, along with Amolyt’s skilled team and early-stage pipeline, will support Alexion's expansion into the field of rare endocrinology.

The acquisition agreement stipulates that AstraZeneca has acquired all of Amolyt Pharma’s outstanding shares for a total price of up to $1.05 billion, on a cash and debt-free basis. This includes an initial payment of $800 million at the deal's closure, with an additional contingent payment of $250 million to be paid upon reaching a specific regulatory milestone.

Amolyt Pharma is dedicated to developing transformative treatments for patients with rare endocrine and related diseases. Its development portfolio includes eneboparatide, a long-acting PTH1 receptor agonist intended as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist aimed at treating acromegaly.

Amolyt Pharma leverages its team’s expertise to advance these innovative treatments, promising significant benefits for patients suffering from these rare conditions.